tam8 Antibody

What is TEM8 and why is it a valuable target for antibody development?

TEM8 is a cell membrane protein predominantly expressed in tumor endothelium and has been identified as a receptor for anthrax toxin. Its value as a therapeutic target stems from its widespread stromal expression in approximately 71% of analyzed tumors while remaining largely undetectable in corresponding normal tissues. This differential expression pattern makes TEM8 an ideal candidate for targeted cancer therapies, particularly antibody-drug conjugates (ADCs) . TEM8 shares 54% amino acid extracellular domain identity with CMG2 (Capillary Morphogenesis Protein-2), another anthrax toxin receptor, but high-affinity antibodies can be developed with specificity for TEM8 alone .

What are the structural characteristics of TEM8 that make it suitable for antibody targeting?

TEM8 contains an extracellular domain (ECD) that can be specifically targeted by antibodies. High-affinity antibodies such as m825 have been developed with a binding affinity (KD) of 59 pM, showing excellent specificity for TEM8 without cross-reactivity to its homolog CMG2 . The antibody m825 was developed by screening a diverse human scFv yeast antibody display library against mouse and human TEM8 ECD. This approach avoids tolerance mechanisms, allowing identification of antibodies against highly conserved epitopes. The resulting antibody demonstrates specific internalization into TEM8+ cells and favorable production characteristics including high yields and stability .

How do TEM8 antibodies function as antibody-drug conjugates (ADCs) in cancer therapy?

TEM8 antibodies have been successfully developed into ADCs, such as m825-MMAE, which shows potent tumor-regressing activity against multiple cancer types. These ADCs function through an unexpected tumor-killing mechanism that depends on tumor-associated stroma rather than direct action on cancer cells . When TEM8 ADCs bind to their target on stromal cells, they are internalized, allowing the conjugated cytotoxic drug to be released within the tumor microenvironment. This approach leverages the differential expression of TEM8 in tumor stroma versus normal tissues to deliver cytotoxic payloads specifically to the tumor site, potentially minimizing off-target effects .

How do engineered TEM8-Fc molecules compare with conventional TEM8 antibodies in antitumor activity?

TEM8-Fc is an engineered antibody-like molecule consisting of the protective antigen (PA)-binding domain of human TEM8 linked to the Fc portion of human immunoglobulin G1. Unlike conventional antibodies that directly target TEM8, TEM8-Fc acts as a decoy receptor that can interact with the M2 isoenzyme of pyruvate kinase (M2-PK), which plays an important role in tumor growth and metastasis .

In xenograft human tumor models in athymic nude mice, TEM8-Fc demonstrated significant suppression of tumor growth across multiple cancer types:

• LS-180 tumors: mean weight reduction from 1.72g (control) to 0.16g (10 mg/kg TEM8-Fc), difference = 1.56g, 95% CI = 0.96 to 2.16g; P<0.001

• MCF-7 tumors: mean weight reduction from 1.12g to 0.08g, difference = 1.04g, 95% CI = 0.77 to 1.31g; P<0.001

• HepG2 tumors: mean weight reduction from 1.28g to 0.35g, difference = 0.93g, 95% CI = 0.60 to 1.25g; P<0.001

These results demonstrate that engineered TEM8-Fc constructs can effectively suppress tumor growth, potentially through a mechanism involving M2-PK trapping.

What detection methods and assays are optimal for evaluating TEM8 expression in tissue samples?

For detecting TEM8 expression in tissues, both immunohistochemistry (IHC) on FFPE samples and immunofluorescence (IF) on frozen sections have been employed with varying sensitivity. Research suggests that IF on frozen sections may provide more reliable detection of TEM8, as the antigen appears sensitive to FFPE fixation conditions, potentially leading to underestimation of TEM8 positivity in FFPE samples .

For antibody development and specificity testing, multiple techniques have proven valuable:

• Immunoprecipitation (IP) to test antibody specificity

• Flow cytometry using cells expressing mouse or human TEM8 or CMG2

• Immunoblotting against TEM8-GST deletion series for epitope mapping

• Peptide mapping to identify specific binding regions

When developing new anti-TEM8 antibodies, it's crucial to verify specificity against potential cross-reactive proteins, particularly CMG2 (ANTXR2) which shares significant homology with TEM8.

How does the tumor microenvironment influence the efficacy of TEM8-targeted therapies?

The tumor microenvironment plays a critical role in determining the efficacy of TEM8-targeted therapies since TEM8 expression is predominantly found in tumor-associated stroma rather than cancer cells themselves. Studies comparing tumor growth in TEM8 wild-type versus knockout mice have shown significantly delayed growth of breast, colon, lung, and melanoma tumors in the absence of TEM8, highlighting its importance in tumor progression .

The efficacy of TEM8 antibody therapies depends on several factors within the tumor microenvironment:

• Accessibility of stromal TEM8 to antibodies in the circulation

• Internalization rate of TEM8 upon antibody binding

• Local immune response and potential antibody-dependent cellular cytotoxicity

• Stromal density and composition, which may vary across tumor types

While treatment with naked TEM8 antibodies has been shown to slow tumor growth and prolong survival in preclinical models, this effect appears to be limited, with no complete tumor regressions observed with monotherapy . This suggests that the tumor microenvironment may impose certain limitations on antibody-mediated targeting of TEM8 that can be potentially overcome by developing more potent ADCs or combination therapies.

What are the mechanisms underlying tumor regression with TEM8 antibody-drug conjugates?

TEM8 ADCs, such as m825-MMAE, demonstrate potent tumor-regressing activity through a mechanism that depends on tumor-associated stroma. Unlike conventional ADCs that directly target cancer cells, TEM8 ADCs exploit the differential expression of TEM8 in tumor stroma to deliver cytotoxic payloads to the tumor microenvironment .

The proposed mechanism involves:

• Binding of the ADC to TEM8 expressed on stromal cells within the tumor microenvironment

• Internalization of the ADC-TEM8 complex into stromal cells

• Release of the cytotoxic payload (e.g., MMAE) within stromal cells

• Disruption of the tumor-supporting stromal architecture

• Indirect effects on adjacent tumor cells, potentially through bystander killing or disruption of stromal support

This mechanism represents a paradigm shift from traditional cancer-cell-directed therapies to stromal-directed approaches, potentially offering advantages for tumors with limited targetable cancer cell antigens but abundant stromal components .

How do TEM8 antibodies interact with the ANTXR family proteins and what are the implications for cross-reactivity?

TEM8 (also known as ANTXR1) shares significant homology with CMG2 (ANTXR2), both members of the ANTXR family identified as anthrax toxin receptors. High-specificity TEM8 antibodies must discriminate between these related proteins to avoid unwanted cross-reactivity .

The m825 antibody demonstrates exclusive binding to murine and human TEM8 without detectable binding to CMG2, as verified through immunoprecipitation and flow cytometric studies with TEM8- or CMG2-expressing cells . This specificity is crucial for therapeutic applications to prevent off-target effects on CMG2-expressing tissues.

Interestingly, research has identified a previously uncharacterized third ANTXR family member, designated ANTXRL, with full-length ORFs encoding putative transmembrane receptors in both human and mouse (GenBank accession numbers KY947541 and KY947542) . The discovery of this additional family member highlights the importance of comprehensive specificity testing for TEM8 antibodies against all potential cross-reactive proteins within the ANTXR family.

What are the optimal approaches for developing high-specificity TEM8 antibodies?

Developing high-specificity TEM8 antibodies requires careful consideration of epitope selection, antibody screening methodologies, and validation approaches:

• Epitope Selection:

  • Target regions with low homology to related proteins (particularly CMG2/ANTXR2)

  • Consider extracellular domains that are accessible in the native conformation

  • The 15-amino acid N-terminal region that is 100% conserved between mouse and human TEM8 has proven valuable for antibody development

• Antibody Generation Strategies:

  • In vitro antibody display using yeast or phage libraries can avoid tolerance mechanisms, enabling isolation of antibodies against highly conserved epitopes

  • Immunization with purified TEM8 extracellular domain followed by hybridoma development

  • Screening against both mouse and human TEM8 can identify cross-reactive antibodies valuable for translational research

• Validation Methodologies:

  • Multi-platform specificity testing (IP, flow cytometry, immunoblotting)

  • Epitope mapping through deletion constructs and peptide arrays

  • Verification of binding to native TEM8 on cells versus related proteins like CMG2

  • Functional testing of internalization capacity, which is critical for ADC development

The m825 antibody exemplifies successful development, showing high affinity (KD: 59 pM), specific internalization into TEM8+ cells, and favorable production characteristics .

How should researchers optimize detection of TEM8 expression in clinical samples?

Optimal detection of TEM8 expression in clinical samples requires consideration of sample preparation, antibody selection, and detection techniques:

• Sample Preparation:

  • Fresh frozen tissue sections appear to provide more reliable TEM8 detection than FFPE samples due to antigen sensitivity to fixation conditions

  • If using FFPE samples, systematic optimization of antigen retrieval methods is essential

  • Consider dual approach of both IHC and IF for comprehensive assessment

• Antibody Selection:

  • Use antibodies with validated specificity against TEM8 versus CMG2

  • Consider antibodies targeting conserved epitopes for cross-species reactivity

  • The rabbit monoclonal antibody (clone 37) targeting the TEM8 extracellular domain has demonstrated efficacy for IHC applications

• Detection Protocols:

  • For IHC, detailed protocols with optimized antigen retrieval and detection systems should be established

  • For IF, protocols minimizing background while maximizing specific signal are essential

  • Positive and negative controls should include TEM8 knockout tissues and CMG2-expressing tissues to confirm specificity

Researchers should be aware that TEM8 positivity in FFPE tumor tissues may be underestimated due to antigen sensitivity to fixation conditions, as noted for other antibodies .

What are the critical parameters for evaluating TEM8 antibody-drug conjugates in preclinical models?

Evaluation of TEM8 ADCs in preclinical models requires consideration of several critical parameters:

• Selection of Appropriate Models:

  • Models should recapitulate human tumor stromal architecture with TEM8 expression

  • Consider multiple tumor types (breast, colon, lung, melanoma) to assess broad applicability

  • Inclusion of TEM8 knockout models as controls to confirm target specificity

• ADC Design Considerations:

  • Linker chemistry optimization for stability in circulation but cleavability in target cells

  • Payload selection based on mechanism of action and bystander effect potential

  • Antibody affinity and internalization rate assessment

• Efficacy Evaluation Parameters:

  • Tumor growth inhibition and regression metrics

  • Survival benefit assessment

  • Dose-response relationship characterization

  • Pharmacokinetic/pharmacodynamic correlation

• Safety Assessment:

  • Toxicity profile in relation to normal tissue TEM8 expression

  • Assessment of off-target effects

  • Evaluation of immune-mediated adverse events

• Mechanism of Action Studies:

  • Confirmation of stromal targeting versus direct tumor cell effects

  • Evaluation of bystander killing potential

  • Analysis of stromal disruption and resulting effects on tumor viability

Comprehensive evaluation across these parameters will provide crucial insights into the therapeutic potential and optimal development path for TEM8 ADCs.

How might TEM8 antibodies be integrated into combination immunotherapy approaches?

TEM8 antibodies offer distinctive mechanisms for targeting the tumor microenvironment, potentially complementing existing immunotherapies through:

• Stromal Modulation: TEM8 antibodies could disrupt the protective stromal barrier that often limits immune cell infiltration into tumors. By targeting TEM8-expressing stromal cells, these antibodies could potentially increase tumor accessibility to immune effector cells, enhancing the efficacy of checkpoint inhibitors .

• Enhanced Antigen Presentation: Disruption of tumor stroma through TEM8 targeting might increase tumor antigen release and presentation, potentially converting "cold" tumors (lacking immune infiltration) to "hot" tumors more responsive to immunotherapy.

• Multipronged Targeting Approaches: Combining TEM8 ADCs with immune checkpoint inhibitors could simultaneously address both stromal barriers and T-cell exhaustion, potentially overcoming resistance mechanisms to either approach alone.

• Sequential Therapy Strategies: TEM8 antibody therapy could be employed as a priming strategy before immunotherapy to modify the tumor microenvironment, potentially enhancing subsequent immune-mediated responses.

Future research should systematically evaluate these combinatorial approaches, establishing optimal sequencing, dosing, and patient selection criteria for integrated TEM8 antibody-immunotherapy regimens.

What emerging technologies might enhance TEM8 antibody development and application?

Several emerging technologies hold promise for advancing TEM8 antibody development and application:

• Bispecific Antibody Platforms: Developing bispecific antibodies that simultaneously target TEM8 and immune effector cells (T cells, NK cells) could enhance therapeutic efficacy through direct immune recruitment to tumor stroma.

• Novel Payload Technologies: Beyond conventional cytotoxic agents, emerging payloads including immunomodulatory molecules, DNA-damaging agents, or targeted protein degraders could expand the therapeutic potential of TEM8 ADCs.

• Antibody Fragment and Alternative Scaffold Approaches: Smaller antibody formats or non-antibody scaffolds targeting TEM8 might offer advantages in tissue penetration, particularly for dense stromal tumors.

• Advanced Imaging Applications: TEM8 antibodies conjugated to novel imaging agents could facilitate non-invasive assessment of the tumor microenvironment, potentially enabling patient selection and response monitoring.

• CRISPR-Based Functional Genomics: Systematic CRISPR screening approaches could identify synthetic lethal interactions with TEM8 inhibition, informing rational combination strategies.

These technological advancements could significantly expand the utility and efficacy of TEM8-targeted therapeutic approaches in cancer.

What biomarkers might predict response to TEM8-targeted therapies?

Identifying predictive biomarkers for response to TEM8-targeted therapies represents a critical research priority. Potential biomarker approaches include:

• TEM8 Expression Profiling: Comprehensive assessment of TEM8 expression patterns across tumor and stromal compartments might predict therapeutic response. Techniques such as multiplex immunofluorescence or spatial transcriptomics could provide detailed spatial information about TEM8 distribution .

• Stromal Signature Assessment: Beyond TEM8 itself, broader stromal gene expression signatures might identify tumors particularly dependent on stromal support and thus potentially responsive to TEM8-targeted disruption.

• Immune Contexture Analysis: Characterization of pre-existing immune infiltrates and their relationship to TEM8-expressing stromal regions could inform combination strategies and identify patients likely to benefit from combined TEM8-immunotherapy approaches.

• Vascular Perfusion Markers: Since TEM8 was originally identified as a tumor endothelial marker, assessment of vascular architecture and function might correlate with response to TEM8-targeted therapies.

• M2-PK Levels: Given the interaction between TEM8 and the M2 isoenzyme of pyruvate kinase (M2-PK), measurement of circulating or tumor-associated M2-PK might serve as a biomarker for tumors particularly susceptible to TEM8-Fc intervention .

Integration of these biomarker approaches into early-phase clinical development will be essential for identifying patient populations most likely to benefit from TEM8-targeted therapeutic strategies.